TRML Insider Trading

Insider Ownership Percentage: 16.50%
Insider Buying (Last 12 Months): $3,765,022.00
Insider Selling (Last 12 Months): $0.00

Tourmaline Bio Insider Trading History Chart

This chart shows the insider buying and selling history at Tourmaline Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Tourmaline Bio Share Price & Price History

Current Price: $20.15
Price Change: Price Increase of +0.05 (0.25%)
As of 04/12/2024 05:00 PM ET

This chart shows the closing price history over time for TRML up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Tourmaline Bio Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/29/2024Mark McdadeDirectorBuy100,000$32.50$3,250,000.00448,431View SEC Filing Icon  
11/17/2023Parvinder ThiaraDirectorBuy1,000$17.31$17,310.0083,782View SEC Filing Icon  
11/17/2023Sandeep Chidambar KulkarniCEOBuy4,000$16.99$67,960.00729,735View SEC Filing Icon  
10/27/2023Caley CasteleinDirectorBuy15,800$14.55$229,890.00516,519View SEC Filing Icon  
10/26/2023Sandeep Chidambar KulkarniCEOBuy5,000$12.25$61,250.00725,735View SEC Filing Icon  
10/24/2023Aaron KantoffDirectorBuy7,500$11.86$88,950.0045,391View SEC Filing Icon  
10/24/2023Sandeep Chidambar KulkarniCEOBuy4,650$10.68$49,662.00720,735View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Tourmaline Bio (NASDAQ:TRML)

91.89% of Tourmaline Bio stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at TRML by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Tourmaline Bio Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
3/11/2024Vanguard Group Inc.763,752$20M0.0%N/A3.755%Search for SEC Filing on Google Icon
3/1/2024Goldman Sachs Group Inc.9,003$0.24M0.0%N/A0.044%Search for SEC Filing on Google Icon
2/15/2024Blue Owl Capital Holdings LP1,332,302$32.39M5.9%N/A6.551%Search for SEC Filing on Google Icon
2/15/2024Vanguard Group Inc.763,752$20M0.0%N/A3.755%Search for SEC Filing on Google Icon
2/15/2024Velan Capital Investment Management LP319,080$8.35M4.9%N/A1.569%Search for SEC Filing on Google Icon
2/15/2024Nantahala Capital Management LLC410,907$10.76M0.6%N/A2.020%Search for SEC Filing on Google Icon
2/15/2024Great Point Partners LLC672,885$17.62M3.0%N/A3.308%Search for SEC Filing on Google Icon
2/15/2024Bridgeway Capital Management LLC32,117$0.84M0.0%N/A0.158%Search for SEC Filing on Google Icon
2/14/2024Braidwell LP906,820$23.74M0.9%N/A4.458%Search for SEC Filing on Google Icon
2/14/2024Cubist Systematic Strategies LLC15,241$0.40M0.0%N/A0.075%Search for SEC Filing on Google Icon
2/14/2024Avoro Capital Advisors LLC868,407$22.74M0.3%N/A4.269%Search for SEC Filing on Google Icon
2/14/2024Balyasny Asset Management L.P.344,127$9.01M0.0%N/A1.692%Search for SEC Filing on Google Icon
2/14/2024RTW Investments LP398,850$10.44M0.2%N/A1.961%Search for SEC Filing on Google Icon
2/13/2024Northern Trust Corp22,373$0.59M0.0%N/A0.110%Search for SEC Filing on Google Icon
2/13/2024Affinity Asset Advisors LLC68,081$1.78M0.3%N/A0.335%Search for SEC Filing on Google Icon
2/13/2024Goldman Sachs Group Inc.9,003$0.24M0.0%N/A0.044%Search for SEC Filing on Google Icon
2/7/2024Dimensional Fund Advisors LP20,868$0.55M0.0%N/A0.103%Search for SEC Filing on Google Icon
2/7/2024Jump Financial LLC14,500$0.38M0.0%N/A0.071%Search for SEC Filing on Google Icon
2/7/2024Vivo Capital LLC591,882$15.50M1.3%N/A2.910%Search for SEC Filing on Google Icon
1/30/2024BML Capital Management LLC245,500$6.43M4.9%N/A1.207%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Tourmaline Bio logo
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline also comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). Tourmaline Bio, Inc. was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.
Read More on Tourmaline Bio

Today's Range

Now: $20.15
Low: $19.42
High: $21.07

50 Day Range

MA: $34.14
Low: $19.91
High: $45.64

52 Week Range

Now: $20.15
Low: $9.18
High: $48.31

Volume

312,659 shs

Average Volume

351,867 shs

Market Capitalization

$516.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.33

Who are the company insiders with the largest holdings of Tourmaline Bio?

Tourmaline Bio's top insider shareholders include:
  1. Sandeep Chidambar Kulkarni (CEO)
  2. Caley Castelein (Director)
  3. Mark Mcdade (Director)
  4. Parvinder Thiara (Director)
  5. Aaron Kantoff (Director)
Learn More about top insider investors at Tourmaline Bio.